Examples include clinical trials in HER2 positive gastric cancer [6], the Viktory umbrella trial in gastric cancer [7], the approval of targeted therapies for cholangiocarcinomas with FGFR2 fusions or rearrangements [8], or the use of a triple targeted therapy in BRAF mutated colon cancer [9]. The gene discussed is BRAF; the disease is gastric cancer.